![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » UK’s NICE Recommends Gilead’s and Galapagos’ Rheumatoid Arthritis Drug
UK’s NICE Recommends Gilead’s and Galapagos’ Rheumatoid Arthritis Drug
![NICE-logo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/NICE-logo.gif?t=1604717099&width=430)
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Gilead Sciences’ and Galapagos’ Jyseleca (filgotinib) for National Health Service coverage as a treatment for rheumatoid arthritis.
The once-daily oral pill can be given as a monotherapy or with methotrexate. To qualify for the drug, patients must have responded poorly to two or more conventional disease-modifying anti-rheumatic drugs.
Gilead Sciences recently announced that it would no longer pursue FDA approval for Jyseleca and it downgraded a multibillion-dollar development pact with Galapagos.
Upcoming Events
-
21Oct